T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Relatlimab
Related studies linked through entity extraction aliases.
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
- Status
- COMPLETED
- Phase
- PHASE1
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- Status
- TERMINATED
- Phase
- PHASE1
Pan Tumor Rollover Study
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
- Status
- TERMINATED
- Phase
- PHASE2
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
- Status
- COMPLETED
- Phase
- PHASE2
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
- Status
- COMPLETED
- Phase
- PHASE1
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1